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The association of preoperative serum tumour markers with Dukes' stage
and survival in colorectal cancer
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S Taryhe tumour markers carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), TPS, CA
19-9, CA 50 and CA 242 were analysed in serum from 203 potentially curable colorectal cancer patients. The
levels of all markers increased with increasing tumour stage, and all markers correlated with survival.
Multivariate analyses indicated that the Dukes stage had the best prognostic explanatory power, followed by
TPA. In the subset of 166 potentially cured patients, the prognostic information by the markers was
substantially reduced. We conclude that preoperative serum tumour marker measurements have the potential
to aid therapy selection, but also that their clinical usefiulness is not immediately apparent.
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The Dukes classification, although known only post-
operatively, constitutes the best-known marker for staging
and prognosis in colorectal cancer (Jass et al., 1986). Patients
with superficial tumours in Dukes' stage A are generally
cured by surgery alone, and additional therapy is not
indicated. In Dukes' stage D, when the disease is metastatic,
treatment usually only serves as palliation. When the tumour
has penetrated through the muscularis propria layer (Dukes'
stage B), or when present in the regional lymph nodes
(Dukes' stage C), the overall 5 year survival rate reaches only
about 70% and 45% respectively. As additional treatment,
possibly initiated early perioperatively, has been shown in
recent studies (Moertel et al., 1990) to increase the overall
survival rate, there is a need to select tools superior to but
also available earlier than the Dukes stage.
The use of several serum tumour markers in colorectal
cancer has been proposed with this intention (Moore et al.,
1990). Using a first generation of tumour markers, CEA
(carcinoembryonic antigen) and TPA (tissue polypeptide
antigen), a correlation between the preoperative serum level
and survival has been demonstrated. Some studies have also
shown that CEA or TPA provides information additional to
Dukes' stage (StAhle et al., 1988a; Chu et al., 1991), while
this has not been demonstrated in other studies (Lewi et al.,
1984; Moertel et al., 1986).
New antigens, such as CA 50 and CA 19-9, may provide
further prognostic information (Koprowski et al., 1979;
Holmgren et al., 1984). However, these new generation
tumour markers have not given improved predictive inform-
ation as expected (Holmgren et al., 1984; Kuusela et al.,
1984; Gupta et al., 1985; Cangemi et al., 1987; Putzki et al.,
1987; Johansson et al., 1991).
In previous studies from our group, the preoperative serum
levels of three tumour markers, CEA, TPA and CA 50,
provided prognostic information for rectal cancer (Stihle et
al., 1988b). The best combination of these tumour markers
together with polyploid tumour growth gave, from a statis-
tical point of view, preoperative prognostic information of
the same order as that of the Dukes stage post-operatively.
Post-operatively, the serum markers improved the prognostic
pedictability of Dukes' stage. The aim of this study was to
evaluate the same markers in independent material, including
also colon cancer. In addition, CA 19-9 and two more
recently reported markers, CA 242 (Nilsson et al., 1992) and
TPS (Cooper et al., 1992), were included to explore whether




Between February 1987 and November 1992, preoperative
serum was collected from 203 consecutive patients with col-
orectal cancer (102 colon; 101 rectum) considered to be
potentially curable. There were 107 men (mean age 70 years,
range 35-89) and 96 women (mean age 70 years, range
40-94). The tumour was radically excised (Dukes' stages
A-C) in 166 patients (Dukes and Bussey, 1958). Thirty-seven
patients had either non-radical surgery or distant metastases
(Dukes' stage D). The preoperative routines included
physical examination, simple laboratory tests (erythrocyte
sedimentation rate, blood haemoglobin, B-leucocyte count,
serum bilirubin, aspartate and alanine aminotransferases and
ALP), endoscopy, barium enema and pulmonary radio-
graphs. Seventy-three (36%) patients had died from cancer
on follow-up to the end of 1993. Patients with known recur-
rence were considered to have died from the disease irrespec-
tive of the stated cause. Median survival time of living
patients was 45 months (range 13-82).
Twnour markers
Each tumour marker was analysed using an immunoradio-
metric (IRMA) technique without knowledge of Dukes' stage
and clinical outcome. CEA, TPA, and CA 19-9 were
analysed by AB Sangtec Medical, Bromma, Sweden; CA 50
and CA 242 by Pharmacia CanAg, Gothenberg, Sweden; and
TPS by BEKI Diagnostics, Bromma, Sweden.
Statistical methods
In order to study the effects on survival of different variables
alone or while simultaneously adjusting for the effects of
other variables, the Cox proportional hazards model was
used (Lawless, 1982).
Wald, score and likelihood ratio tests were used to test for
significance. In the development of models based on stepwise
criteria, we in general used the score statistic. As a measure
of the explanatory value of a model, an R2-type statistic
(denoted R2) based on the log likelihood value and the
number of explanatory variables in the models was used.
Standard F-tests based on original and log-transformed
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Table I The distributions of the tumour marlkers in original form in the entire study population and in
the different Dukes' stages. Q3-QI is the interquartile range
Total Dukes' stage (median)
Twnour marker Mean Median QJ Q3 A B C D
CEA 26.3 4.1 2.2 14.0 2.0 4.4 4.0 26.8
CA 19-9 35.2 15.9 8.7 47.7 17.2 15.7 16.0 13.1
CA 50 1279.5 22.0 11.1 46.3 11.6 21.3 21.9 41.5
CA 242 991.0 16.2 6.9 46.3 6.2 18.6 15.5 69.6
TPA 200.5 61.0 44.0 117.0 47.0 60.5 60.5 277.0
TPS 208.7 73.0 40.0 131.0 67.5 66.0 74.5 101.0
Table H Sensitivity of tumour markers in different Dukes' stages using commercially given normal cut-off levels
(cut-off levels defined as the highest levels among 95% of healthy blood donors)
CEA
CEA CA 19-9 CA 50 CA 242 TPA TPS CEA CA19-9
Dukes' stage No. >4.0 >14.0 >45.0 >20.0 >95.0 >80.0 TPA TPA
A 35 7 (20) 10 (27) 7 (20) 8 (23) 5 (14) 13 (37) 2 (6) 2 (6)
B 87 45 (52) 51 (59) 15 (17) 40 (46) 19 (22) 28 (32) 11 (13) 5 (6)
C 44 23 (52) 25 (57) 13 (30) 20 (45) 12 (27) 19 (43) 7 (16) 4 (9)
D 37 32 (86) 23 (62) 16 (43) 21 (57) 24 (65) 29 (78) 22 (59) 19 (51)
Figures are number of patients with elevated levels (per cent). When different combinations of tumour markers are
used, the figures are number of patients with an elevated level of all tumour markers (per cent).
data and non-parametric Kruskal-Wallis tests were used to
test for differences in continuous variables between different
groups (e.g. Dukes' stage).
Results
General distribution and relation to Dukes' stage
In original form, the distributions of all markers were
strongly skewed. Logarithmic transformation reduced the
skewness considerably. The distributions of the six tumour
markers in the whole study population and in the different
Dukes' stages are shown in Table I. All the markers were
correlated. Pairwise correlations above 0.7 based on logarith-
mic values were found for CA 19-9/CA 50, CA 19-9/CA 242,
CA 50/CA 242 and TPAFITPS (data not shown).
A significant overall difference at the 5% level between
different Dukes' stages was seen for all variables. The way
the various markers discriminated between the different
stages was, however, different. In pairwise comparisons, all
markers but CA 19-9 in Dukes' stage D differed from the
other stages. For CA .19-9, CEA and CA 242, there was a
significant difference between Dukes' stage A and the remain-
ing stages (data not shown).
The numbers of patients in each Dukes' stage with tumour
markers above commercially given normal cut-off levels are
given in Table II. In the Dukes' stages A-C taken together,
the tumour markers were elevated by between 21 % and 52%.
In Dukes' stage D, the corresponding figures were 43-78%.
The combinations of two (e.g. CEA/TPA) or three (e.g.
CEA/CA 19-9/TPA) markers reduced the proportion of
potentially cured patients demonstrating elevated tumour
marker levels (12% and 7% respectively) (Table II).
Twnour mrarker levels andprognosis ofpotentially curable
patients
As continuous variables, all markers were strongly correlated
with survival. The strongest significance was seen for TPA
(Table III). When categorised into quartiles, the RH (relative
hazard) of the highest quartile was always significantly
elevated compared with the first quartile. Moreover, the RH
was significantly higher for CEA and TPS in the third quar-
tile and for CA 50 in the second quartile than in the first
quartile (Table IV).
In multivariate analyses of the tumour markers, in
logarithmic form, TPA was the most important variable.
Table m The relation between the preoperative serum levels
(logarithmic form), and survival for the potentially curable patients
(n =203)
X2
Variable p s.e. (p) Wald test
CEA 0.3661 0.0679 29.09
CA 19-9 0.2747 0.0918 8.96
CA 50 0.3855 0.0633 37.09
CA 242 0.3085 0.0561 30.20
TPA 0.8081 0.1013 63.58
TPS 0.6516 0.0913 51.08
x2 denotes a chi-square value (with one degree of freedom).
Univariate Cox PH analyses. Significance levels:'5% X9>3.84; 1%
x2>6.63; 0.1% x2> 10.83.
CEA provided significant additional information. The other
four markers were insignificant in a model with TPA and
CEA. The RHs per unit of the variables in log scale were 2.2
(95% CL 1.2-2.7) for TPA and 1.2 (95% CL 1.1-1.4) for
CEA.
There was a gradual elevation in the risk of death with
increasing Dukes' stage (Table IV). All variables gave
significant additional information to Dukes' stage (Table V),
but none of the remaining five markers provided significant
further information in a model that contained Dukes' stage
and TPA (data not shown). TPA and TPS gave very similar
results.
The explanatory value (RJ) of Dukes' stage alone was
0.104. This value was higher than the best combination of
serum markers, a combination of TPA and CEA in logarith-
mic form, R2 = 0.078. The best single serum marker, TPA,
also gave a slightly lower value, R2 =0.069. When Dukes'
stage was combined with the serum marker giving the highest
additional information, the value increased to 0.123, thus
indicating that TPA enhanced the prognostic information
beyond that of the Dukes' stage.
Tumour marker levels andprognosis ofpotentially cured
patients
In this group of patients, CEA and TPA were the only
tumour markers providing prognostic information (P<0.01
and P<0.05) in univariate analyses (Table VI). In several
cases the explanatory power of the variables in orginal form
was greater in this case. In multivariate analyses, none of the
other markers provided significant additional information to
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Table IV The relationship between Dukes' stages and survival and tumour
markers categorised into quartie and suvival (RH, relative hazard)
95% conidwe X2
Variable Quatie No. RH limits Wald test
Dukes' stage
A 35 1.00 (ret)
B 87 2.05 (0.70-6.04)
C 44 4.48 (1.53-13.17) 7.32
D 37 20.29 (70.4-58.46) 31.47
CEA
<2.2 55 1.00 (ret)
2.2-4.1 47 1.73 (0.72-4.19)
4.2-14.0 51 3.42 (1.53-7.64) 8.93
>14.0 50 5.26 (2.40-11.52) 17.14
CA 19-9
<8.7 50 1.00 (ret)
8.7-15.9 51 0.82 (0.38-1.76)
16.0-47.9 51 1.27 (0.64-2.52)
>47.9 50 2.51 (1.34-4.70) 8.16
CA 50
<11.1 52 1.00 (ret)
11.1-22.0 50 2.20 (1.03-4.73) 3.98
22.1-46.3 51 2.03 (0.93-4.45)
>46.3 50 3.78 (1.83-7.81) 12.95
CA 242
<6.9 51 1.00 (ref)
6.9-16.2 51 1.15 (0.56-2.38)
16.3-46.3 51 1.03 (0.49-2.17)
>46.3 50 2.80 (1.47-5.35) 9.97
TPA
<44.0 52 1.00 (ret)
44.0-61.0 54 1.32 (0.63-2.79)
61.1-117.0 47 1.05 (0.46-2.39)
>117.0 50 4.81 (2.47-9.36) 21.58
TPS
<40.0 52 1.00 (ret)
40.0-73.0 51 1.73 (0.75-4.03)
73.1-131.0 47 2.51 (1.15-5.50) 5.11
>131.0 50 6.55 (3.11-13.80) 23.90
Univariate Cox PH analyses. Significance leves: 5% X>3.84; 1% x>6.63;
0.1% X2>10.83.
Tabe V The prognostic value of each tumour marker (logarithmic
form) when taking the Dukes stag nto account
XI
s.e. (p) Wald test
CEA 0.165 0.069 5.66
CA 19-9 0.272 0.089 9.22
CA 50 0.272 0.062 19.43
CA 242 0.217 0.055 15.40
TPA 0.553 0.110 25.52
TlPS 0.550 0.105 27.22
Significance lels: 5% X2>3.84; 1% X2>6.63; 0.1% X2>10.83.
a model that included CEA (data not shown). Adjustment
for Dukes' stage reduced the signifi of the variables.
TPA was the most important variable after such an adjust-
ment.
Disc_m
Every tested serum marker gave prognostic information in
the group of patients of interest for pre- or peroperatively
initiated additional treatment, i.e. patients in whom major
surgery with curative intent was planned, revealing their
possible importance for the selection of additional treatment.
Also, in the group of patients of interest for prolonged
post-operative adjuvant treatment, i.e. potentially cured
patients (Dukes' stages A-C), the markers gave prognostic
information. However, only some of them then kept their
independent prognostic information, and without being
highly significant.
We could confirm the potential value of the tumour
markers CEA, CA 50 and TPA both for staging and for
prediction of survival, which we previously reported in a
separate study on rectal cancer only (Stihle et al., 1988ab,
1989). We also found that the three other tumour markers,
CA 19-9, CA 242 and TPS, can be used for the same
purposes. However, the ability to predict either tumour stage
or prognosis using these new markers did not exceed that of
the oler ones. The prognostic information of the best
tumour marker, TPA, or ofthe best combinations ofmarkers
was not as high as that of the Dukes' stage. Further, when
TPA was analysed in quartiles, only the highest one was
signifintly related to survival. Dukes' stage, in contrast,
was of prognostic importance not only in the highest stage,
even if, in this study, no statistically sigificnt difference was
disclosed between Dukes' stages A and B. Tberefore, it might
be said that the clinical impact of TPA, or any combination
of tumour markers, is not similar to that of the Dukes stage.
The information provided by the markers is, however,
available before surgery.
The prognostic information provided by TPA alone and in
relation to other serm markers and Dukes' stage has now
been reported in two separate patient groups. The relation
between the serum level of TPA and tumour stage was,
however, not the same in this sample as in the previous study
(Stahle et al., 1989). In the former study, which was some-
what larger and only composed of rectal cancer patients, the
serum levels also discriminated between the early stages, and
not only between Dukes' stages A-C and D. This discrep-Setrum &I c i calux can=
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Table VI The relation between the preoperative serum levels (logarithmic
form) and survival for the potentialy cured patients (n = 166)
Unadjusted for Dukes' stage Adyusted for Dukes' stage
Variable X X2
p s.e. (P) Wald test s.e. (P) Wald test
CEA 0.262 0.103 6.45 0.197 0.106 3.44
CA 19-9 0.126 0.114 1.22 0.076 0.110 0.48
CA 50 0.218 0.124 3.09 0.162 0.120 1.81
CA 242 0.156 0.089 3.12 0.096 0.086 1.24
TPA 0.418 0.201 4.30 0.402 0.203 3.90
TPS 0.284 0.156 3.33 0.304 0.158 3.71
x2 denotes a chi-square value (with one degree of freedom). Univariate Cox
PH analyses. Significance levels: 5% x2>3.84; 1% X2>6.63; 0.1% X2>10.83.
ancy is hard to explain, but might be due to the inclusion of
patients with colon cancer. An increased preoperative serum
level of TPA indicates generalised disease and suggests the
need for a careful preoperative examination. Subclinical
metastatic disease would be suspected, however even if other
evidence of metastatic spread were negative, and additional
treatment might be valuable. If this treatment were initiated
post-operatively, the Dukes' stage could be used in the selec-
tion of patients. If, however, the additional treatment were
initiated peroperatively (Taylor et al., 1985; Metzger et al.,
1990), the selection could be aided by, for example, the
preoperative serum level of TPA.
Preoperative irradiation of the pelvis is routinely given at
our hospital to all patients with rectal cancer accepted for
radical surgery (Pahiman and Glimelius, 1992) except when
the tumour is revealed to be confined to the bowel wall by
endosonography (i.e. Dukes' stage A) (Lindmark et al.,
1991). Irradiation is considered unnecessary in Dukes' stage
A owing to the low risk of local recurrence and is of no real
use in Dukes' stage D. The use of the preoperative value of
TPA in the selection of rectal cancer patients for any
preoperatively initiated treatment is not immediately appar-
ent. A TPA level above the normal cut-off value indicates
metastatic disease, and hence preoperative irradiation may
appear superfluous. However, in that group, the 2-year sur-
vival exceeds 40%, which means that a number of patients
are at risk of local recurrence with its known high morbidity.
The majority of local failures occur within 2 years after
surgery.
We conclude that new serum tumour markers should be
investigated in multivariate systems to allow a proper evalua-
tion of their possible clinical usefulness. Serum tumour
markers may be of importance for the selection of patients
for additional therapy in colorectal cancer, but the guidance
they afford is far from absolute and their clinical usefulness
not yet apparent.
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